Krstic-Demonacos, Marija - University of Salford

个人简介

I took up my Chair in Molecular Medicine in the School of Environment & Life Sciences in April 2013. Prior to this I was a Wellcome Trust Fellow and Lecturer at the University of Manchester from 2003. I completed my PhD in molecular endocrinology at the University of California San Francisco and postdoctoral studies in cancer biology at the University of Glasgow. I have published more than 40 papers in reputed journals and am serving as an editorial board member of several international journals. In addition, commercialisation potential of my research is evidenced by the three patents I own. I have presented at numerous conferences and served as reviewer for many international funding bodies and journals.

研究领域

My research focuses on the investigation of mechanisms of gene regulation and cancer biology. In particular, my research group investigates molecular basis of cellular response to hormonal and stress signals, with the aim to analyse gene expression profiles in leukemia associated with drug resistance. My long term interests are in investigating the mechanisms by which clinically relevant drugs mediate their therapeutic effects in order to improve available treatments and to develop novel pharmacologically beneficial approaches. We also study effects of DNA damage on tumor suppressor p53 that is a gene mutated in over half of human cancers. The deregulation of DNA damage inducible signalling pathways plays a major role in the development of cancer and analysis of components of these pathways is vital for the diagnosis, prognosis and therapy of malignant tumours. Finally, my group focuses on pathway modeling and genome wide studies as a tool to understand the mechanisms of cellular signaling and to discover new therapeutic targets. These logical models are increasingly predictive and have potential use in personalized medicine. Commercialization potential of this research is currently being explored as indicated through ownership of three patents demonstrating high potential of for knowledge transfer strategies. Overall my observations provide detailed insight in the molecular networks governing cellular survival in numerous physiological and pathological processes. This knowledge can find application in the pharmaceutical industry, has been highly cited and internationally recognized. Several collaborative projects with clinical partners are ongoing in order to translate this knowledge to clinic and to pursue goals of personalized medicine to generate an efficient roadmap that will lead rapidly and safely to effective individual treatment that will eliminate diseases and create better health care for all.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Chen DW, Saha V, Liu JZ, Schwartz JM, Krstic-Demonacos M. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia, Oncogene, in press, doi: 10.1038/onc.2012.321 Simic I, Adzic M, Maric N, Savic D, Djordjevic J, Mihaljevic M, Mitic M, Pavlovic Z, Soldatovic I, Krstic-Demonacos M, Jasovic-Gasic M, Radojcic M, A preliminary evaluation of leukocyte phospho-glucocorticoid receptor as a potential biomarker of depressogenic vulnerability in healthy adults, Psychiatry Res. 2013 Mar 7. Davies L, Paraskevopoulou E, Sadeq M, Symeou C, Pantelidou C, Demonacos C and Krstic-Demonacos M, Regulation of glucocorticoid receptor function by the stress responsive cofactor, Mol Endocrinology,25, 58-71, 2011 Xenaki G, Onikatze T, Stratford IJ, Dive C, Krstic-Demonacos M, Demonacos, C, PCAF is a HIF-1α cofactor that regulates p53 transcriptional activity in hypoxia, Oncogene, 27, 5785-5796, 2008 Demonacos C, Krstic-Demonacos M, Smith L, Xu D, O'Connor DP, Jansson M, La Thangue NB, A new effector pathway links ATM kinase with the DNA damage response, Nat Cell Biol, 6, 968-976, 2004 Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ, Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor, Mol Cell Biol, 17, 3947-3954, 1997